| A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with … DH Yoo, P Hrycaj, P Miranda, E Ramiterre, M Piotrowski, S Shevchuk, ... Annals of the rheumatic diseases 72 (10), 1613-1620, 2013 | 823 | 2013 |
| A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients … W Park, P Hrycaj, S Jeka, V Kovalenko, G Lysenko, P Miranda, ... Annals of the rheumatic diseases 72 (10), 1605-1612, 2013 | 759 | 2013 |
| Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT … DH Yoo, N Prodanovic, J Jaworski, P Miranda, E Ramiterre, A Lanzon, ... Annals of the rheumatic diseases 76 (2), 355-363, 2017 | 356 | 2017 |
| Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study W Park, DH Yoo, P Miranda, M Brzosko, P Wiland, S Gutierrez-Ureña, ... Annals of the rheumatic diseases 76 (2), 346-354, 2017 | 304 | 2017 |
| Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non … BD Ye, M Pesegova, O Alexeeva, M Osipenko, A Lahat, A Dorofeyev, ... The Lancet 393 (10182), 1699-1707, 2019 | 213 | 2019 |
| Biosimilars for the management of rheumatoid arthritis: economic considerations L Gulacsi, V Brodszky, P Baji, HU Kim, SY Kim, YY Cho, M Pentek Expert review of clinical immunology 11 (sup1), 43-52, 2015 | 132 | 2015 |
| The future of biosimilars: maximizing benefits across immune-mediated inflammatory diseases HU Kim, R Alten, L Avedano, A Dignass, F Gomollón, K Greveson, ... Drugs 80, 99-113, 2020 | 110 | 2020 |
| The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications? S Ben-Horin, GA Heap, T Ahmad, HU Kim, TS Kwon, Y Chowers Expert review of gastroenterology & hepatology 9 (sup1), 27-34, 2015 | 56 | 2015 |
| OP0068 A phase 3 randomised controlled trial to compare CT-P13 with infliximab in patients with active rheumatoid arthritis: 54 week results from the planetra study DH Yoo, A Racewicz, J Brzezicki, R Yatsyshyn, ET Arteaga, ... Annals of the Rheumatic Diseases 72 (Suppl 3), A73-A73, 2013 | 42 | 2013 |
| Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters HU Kim, R Alten, F Cummings, S Danese, G D’Haens, P Emery, S Ghosh, ... MAbs 13 (1), 1868078, 2021 | 24 | 2021 |
| Efficacy and safety of the trastuzumab biosimilar candidate CT-P6 FJ Esteva, T Saeki, HU Kim, J Stebbing Future Oncology 14 (19), 1909-1919, 2018 | 14 | 2018 |
| Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer SY Oh, S Lee, SJ Huh, J Lee, ST Kim, SH Park, HY Lim, WK Kang, ... Cancer chemotherapy and pharmacology 83, 501-508, 2019 | 7 | 2019 |
| Correction to: the future of biosimilars: maximizing benefits across immune-mediated inflammatory diseases HU Kim, R Alten, L Avedano, A Dignass, F Gomollón, K Greveson, ... Drugs 80 (10), 1039, 2020 | 4 | 2020 |
| FRI0104 A LARGE REAL WORLD, LONG TERM SAFETY STUDY OF PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES TREATED WITH INFLIXIMAB BIOSIMILAR (CT-P13): POOLED ANALYSIS OF FOUR GLOBAL … K Baek, YJ Lee, S Lee, H Kim, S Lee, JE Park, SJ Lee Annals of the Rheumatic Diseases 78 (Suppl 2), 718-719, 2019 | 1 | 2019 |
| The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases (vol 80, pg 99, 2020) HU Kim, R Alten, L Avedano, A Dignass, F Gomollon, K Greveson, ... Drugs 80 (10), 1039-1040, 2020 | | 2020 |
| ONLINE RESOURCE 1 FOR HU Kim, R Alten, L Avedano, A Dignass, F Gomollón, K Greveson, ... | | |